IRLAB Therapeutics (OM:IRLAB A) - Aandelenkoers, Nieuws & Analyse

IRLAB A Overzicht aandelen

IRLAB Therapeutics AB (publ) ontwikkelt medicijnen voor de behandeling van de ziekte van Parkinson.

IRLAB A fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 28.59% per jaar groeien

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( SEK731M )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

IRLAB Therapeutics AB (publ) Concurrenten

Enorama Pharma

OM:ERMA

SEK 222.5m

Enzymatica

OM:ENZY

SEK 300.0m

Orexo

OM:ORX

SEK 379.6m

RLS Global

OM:RLS

SEK 35.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor IRLAB Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	SEK 14.10
52 Week Hoogtepunt	SEK 20.20
52 Week Laag	SEK 5.58
Bèta	0.65
11 maand verandering	10.16%
3 maanden verandering	-9.62%
1 Jaar Verandering	107.35%
33 jaar verandering	-68.06%
5 jaar verandering	-58.53%
Verandering sinds IPO	19.49%

Recent nieuws en updates

Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?

Oct 30

Recent updates

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

Mar 18

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

Dec 01

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

May 19

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Sep 11

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Apr 30

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Mar 19

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Jan 25

Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

Dec 21

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Nov 25

Rendement voor aandeelhouders

	IRLAB A	SE Pharmaceuticals	SE Markt
7D	15.6%	-1.5%	-1.4%
1Y	107.4%	38.6%	20.7%

Rendement versus industrie: IRLAB A overtrof de Swedish Pharmaceuticals industrie, die het afgelopen jaar een rendement 38.6 % opleverde.

Rendement versus markt: IRLAB A overtrof de Swedish markt, die het afgelopen jaar een rendement opleverde van 20.7 %.

Prijsvolatiliteit

Is IRLAB A's price volatile compared to industry and market?
IRLAB A volatility
IRLAB A Average Weekly Movement	6.8%
Pharmaceuticals Industry Average Movement	11.1%
Market Average Movement	5.4%
10% most volatile stocks in SE Market	10.8%
10% least volatile stocks in SE Market	3.2%

Stabiele aandelenkoers: IRLAB A heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van IRLAB A is het afgelopen jaar gedaald van 12% naar 7%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	32	Kristina Torfgard	www.irlab.se

IRLAB Therapeutics AB (publ) ontwikkelt geneesmiddelen voor de behandeling van de ziekte van Parkinson. Het bedrijf ontwikkelt Mesdopetam, dat zich in fase IIb/III klinische studies bevindt voor de behandeling van dyskinesie; en Pirepemat, dat zich in fase IIb klinische studie bevindt voor de behandeling van posturale disfunctie. Haar producten in preklinische fase omvatten IRL942, een onderzoeksprogramma voor de behandeling van neurodegeneratieve aandoeningen en veroudering; IRL1117, een kandidaat-geneesmiddel ontwikkeld voor een dagelijkse orale behandeling van de kenmerkende symptomen van Parkinson; en IRL757 voor de behandeling van apathie bij neurologische aandoeningen.

IRLAB Therapeutics AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van IRLAB Therapeutics zich tot de beurswaarde?
IRLAB A fundamentele statistieken
Marktkapitalisatie	SEK 731.34m
Inkomsten(TTM)	-SEK 112.72m
Inkomsten(TTM)	SEK 63.45m

11.5x

P/S-verhouding

-6.5x

Koers/Winstverhouding

Is IRLAB A overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IRLAB A resultatenrekening (TTM)
Inkomsten	SEK 63.45m
Kosten van inkomsten	SEK 120.55m
Brutowinst	-SEK 57.10m
Overige uitgaven	SEK 55.62m
Inkomsten	-SEK 112.72m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 12, 2025

Winst per aandeel (EPS)	-2.17
Brutomarge	-89.99%
Nettowinstmarge	-177.64%
Schuld/Eigen Vermogen Verhouding	138.0%

Hoe presteerde IRLAB A op de lange termijn?

Bekijk historische prestaties en vergelijking

IRLAB A Overzicht aandelen

Beloningen

Risicoanalyse

IRLAB Therapeutics AB (publ) Concurrenten

OM:ERMA

SEK 222.5m

OM:ENZY

SEK 300.0m

OM:ORX

SEK 379.6m

OM:RLS

SEK 35.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New minor risk - Profitability

IRLAB Therapeutics AB (publ) to Report Q2, 2025 Results on Jul 09, 2025

Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?

IRLAB Therapeutics AB Receives Milestone Payment of USD 2.5 Million in Conjunction with First Dosing in A Phase I Study with IRL757 in Healthy Adults

IRLAB Therapeutics AB Announces Positive Data from the First Part of Phase I Study with the Drug Candidate IRL 757

IRLAB Therapeutics AB (publ) Granted Additional Patent for Its Drug Candidate Pirepemat Expanding the Patent Protection in the US

Recent updates

New minor risk - Profitability

IRLAB Therapeutics AB (publ) to Report Q2, 2025 Results on Jul 09, 2025

Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?

IRLAB Therapeutics AB Receives Milestone Payment of USD 2.5 Million in Conjunction with First Dosing in A Phase I Study with IRL757 in Healthy Adults

IRLAB Therapeutics AB Announces Positive Data from the First Part of Phase I Study with the Drug Candidate IRL 757

IRLAB Therapeutics AB (publ) Granted Additional Patent for Its Drug Candidate Pirepemat Expanding the Patent Protection in the US

New minor risk - Profitability

IRLAB Therapeutics AB Announces Phase IIb Study of Pirepemat Can Proceed as Planned After Positive Opinion from External Safety Committee

Price target decreased by 7.1% to kr56.63

IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?

IRLAB Therapeutics AB (publ) Announces CEO Changes, Effective from August 1, 2024

IRLAB Therapeutics AB (publ) Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757

Price target increased by 8.0% to kr60.95

Consensus revenue estimates increase by 178%

Director recently bought kr260k worth of stock

IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757

New major risk - Financial position

IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam

Consensus revenue estimates increase by 88%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Apr 29, 2024

IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines

Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I

IRLAB Therapeutics AB (publ) Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection

New minor risk - Profitability

IRLAB Therapeutics AB (publ) Announces Appointment to its Nomination Committee

Third quarter 2023 earnings released

IRLAB Therapeutics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

Price target increased by 83% to kr59.05

Second quarter 2023 earnings released

IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development

Less than half of directors are independent

IRLAB Therapeutics AB (publ) Elects Christer Nordstedt, Daniel Johnsson and Veronica Wallin as Board Members

IRLAB Therapeutics AB Announces That All Participating Study Sites in the Phase IIb Study of Pirepemat (IRL752) Are Activated and Recruiting Patients

IRLAB Therapeutics AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

IRLAB Therapeutics Updates on Portfolio Development Milestones

IRLAB Therapeutics Announces Top-Line Results from Phase IIb Trial of Mesdopetam (IRL790) in Parkinson’s Disease

IRLAB Therapeutics AB Nominates IRL1117 as Drug Candidate from the P003 Project to Develop a Novel Treatment for Parkinson's Disease

IRLAB Therapeutics AB Reports Last Patient Last Visit (“Lplv”) Achieved in Phase Iib Clinical Study of Mesdopetam in Pd-Lids with Top-Line Results Anticipated Mid-January 2023

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

IRLAB Therapeutics AB (publ) to Report Q1, 2023 Results on May 10, 2023

IRLAB Therapeutics AB Announces New Preclinical Data Indicating Phase IIb Drug Candidate Mesdopetam's Powerful Efficacy in Parkinson's Psychosis and PD-LIDs

IRLAB Therapeutics AB (publ) Appoints Nomination Committee Ahead of Annual General Meeting 2023

IRLAB Completes Recruitment in Phase IIb Study of Mesdopetam (IRL790) in Patients with Parkinson's Levodopa-Induced Dyskinesias

Consensus forecasts updated

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

Consensus forecasts updated

Irlab Therapeutics AB (Publ) Expands Phase IIb/III Pd-Lids Study with Mesdopetam to Support Phase Iii Program and Expects Completion of Enrollment During the Summer

IRLAB Therapeutics AB (publ) Appoints Richard Godfrey as CEO, Effective from 1 July 2022

Chief Financial Officer recently bought kr407k worth of stock

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

IRLAB Therapeutics AB (publ) Approves Board Appointments

Price target increased to kr69.50

Insufficient new directors